Brand/Development Name: Halaven
Principal Therapy Area: Cancer
Eribulin mesylate is a synthetic analogue of halichondrin B, a natural product that has been shown to have highly-potent anticancer activity in vitro and in vivo. Halichondrin B was originally isolated from Halichondria okadai, a type of marine sponge. The compound acts through microtubule growth suppression. Eribulin was developed through a co-operative programme between the National Cancer Institute (NCI) and Eisai Research Institute (ERI). In 1992, ERI scientists determined that the anticancer activity of halichondrin B resides in one half of the molecule. Eribulin was finally isolated following the synthesis of more than 200 analogues of this anticancer half.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org